title: Combined floxuridine and cisplatin in a fourteen day infusion. Phase I study.
abstract: Twenty patients received 28 courses of 5FUDR (floxuridine) admixed with Cisplatin (CDDP) and administered as a continuous infusion for 24 hours for 14 consecutive days. Pharmaceutical studies of the admixture of 5FU with CDDP and 5FUDR with CDDP demonstrated that only 5FUDR was compatible with CDDP and that the admixture was stable for 7 days. This Phase I study established the optimal dose rate for the individual components of the admixture and demonstrated that CDDP decreases the maximum tolerated dose rate for 5FUDR. The optimal dose rate for 5FUDR is 0.075 mg/Kg/d, and for CDDP the optimal dose rate is 7.5 mg/M2/d. Dose rate limiting toxicity is an enteritis which is radiographically similar to regional enteritis and is related to the 5FUDR. An ancillary finding was a significant decrease in serum magnesium levels in 11 of 13 monitored courses presumably related to the platinum.
authors.affiliation: Cancer Center, Medical Center, Boston, MA 02120.
authors.forename: J
authors.initials: J
authors.lastname: Lokich
authors.forename: N
authors.initials: N
authors.lastname: Anderson
authors.forename: M
authors.initials: M
authors.lastname: Bern
authors.forename: S
authors.initials: S
authors.lastname: Wallach
authors.forename: C
authors.initials: C
authors.lastname: Moore
authors.forename: D
authors.initials: D
authors.lastname: Williams
authors.forename: V
authors.initials: V
authors.lastname: Umprain
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D005467:Floxuridine; D002945:Cisplatin